California firm takes cannabinoid research personally

by Invesbrain Tuesday, July 18, 2017
Print This Article

California firm looks to Israel for personalized cannabinoid approach

The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.

California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.

Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.

Both compounds employ an “FDA-approved synthetic THC.”

Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.

(READ MORE)

CMAJ commentary argues for two-stream cannabis system

Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.

In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."

The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”

(READ MORE)

U.S.-German-Israeli deal links cancer diagnostics with cannabinoids

MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”

Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.

SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.

Cannabics’ R&D facility is “concentrated” in Israel.

(READ MORE)

Data on CBD analogue to be presented at neuroscience meeting

Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.

The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”

The firm will also present data on the anti-addictive potential of NB2222.

"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.

(READ MORE)

Former dispensary (TMCD) offers free drug tests and harm reduction supplies in DTES

Vancouver Coastal Health, supporting the initiative, will help in providing the supplies for free, through the BC Centre for Disease Control. Vancouver Coastal Health, the regional health authority that provides health services to Greater Vancouver, has begun supporting the The ...

Can CBD Damage Your Liver?

Now is a crucial time to understand the truth behind CBD. Studies can serve as incredible resources or terrible sources of misinformation. Research taken too seriously can lead someone to wonder if CBD will damage their liver. One would hope their beloved herb is a well-balanced...

GenTech: Second CBD Infusion Café in Trendy Jersey Shore Hotspot

NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — GenTech Holdings, Inc. (OTCMKTS: GTEH) (“GenTech” or the “Company”), an emerging leader in the high-end CBD food and drinks marketplace, is excited to announce plans for the establishment of its second CBD-...

Medical Marijuana Research in Canada Is Going Nowhere

It was said last year that Canada was poised to become a global leader in the realm of medical marijuana research. It made perfect sense, too, what with the country being one of the first to ultimately end marijuana prohibition nationwide. There would be nothing to stop the barr...

July 17, 2019

Inflation does not appear to be a problem: Although two of the Bank of Canada’s measures of core inflation remained above 2 per cent, CPI common – which the central bank says is the best gauge of the economy’s underperformance – was unchanged at 1.8 per cent. Energy pric...

Tech Talk for Thursday July 18th 2019

Pre-opening Comments for Thursday July 18th U.S. equity index futures were mixed this morning. S&P 500 futures were down unchanged in pre-opening trade. Index futures were virtually unchanged following release of economic news released at 8:30 AM EDT. Consensus for Weekly Joble...

Valens GroWorks is well-positioned in emerging edibles space, Mackie Research says

Strong quarterly numbers are cause for a target increase on cannabis extraction company Valens GroWorks (Valens GroWorks News, Stock Quote, Chart TSXV:VGW), according to Mackie Research analyst Greg McLeish, who on Wednesday maintained his “Buy” recommendation while upping h...

DecisionPoint Mid-Week | Possible Short-Term Selling Exhaustion | Bearish Double-Top for USO

It's been a week of consolidation and pullback for the major indexes. Given the look of our very short-term indicators, I would expect to see a move to the upside by Friday or certainly next week. Energy has been struggling and remains the only sector with a Long-Term Trend Mode...

Major Pot Eradication Effort ‘Operation Clean Sweep’ Underway in Emerald Triangle

Major enforcement actions against unlicensed cannabis farms across the Emerald Triangle continued this week, with the Mendocino County Sheriff’s office announcing on Monday that the effort had been named “Operation Clean Sweep” and it was being conducted in tandem with the...

Revolution Enterprises Names Tony Hunter as Board Chairman

ELMHURST, Ill., July 11, 2019 /PRNewswire/ -- Revolution Enterprises CEO Mark de Souza announced today that prominent media executive and corporate leader Tony Hunter will become chair of the company's board of directors. In addition, de Souza said Revolution, a national leader ...